Aytu Biopharma (AYTU) Total Liabilities (2011 - 2026)

Aytu Biopharma (AYTU) has 16 years of Total Liabilities data on file, last reported at $76.5 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $76.5 million, down 14.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $76.5 million (down 14.29% YoY), and the FY2025 annual result was $105.2 million, up 16.41% from the prior year.
• Total Liabilities fell to $76.5 million in Q1 2026 per AYTU's latest filing, from $107.8 million in the prior quarter.
• Over five years, Total Liabilities peaked at $107.8 million in Q4 2025 and troughed at $76.5 million in Q1 2026.
• A 5-year average of $96.6 million and a median of $98.1 million in 2024 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2022 and 2025: Total Liabilities dropped 27.15% in 2022, then increased 26.14% in 2025.
• A 5-year view of Total Liabilities shows it stood at $95.6 million in 2022, then increased by 2.9% to $98.4 million in 2023, then fell by 13.14% to $85.5 million in 2024, then advanced by 26.14% to $107.8 million in 2025, then slipped by 28.99% to $76.5 million in 2026.
• Business Quant data shows AYTU's Total Liabilities at $76.5 million in Q1 2026, $107.8 million in Q4 2025, and $101.8 million in Q3 2025.